You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA643
  • Published:  12 August 2020
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 141 KB)

    Published:
    12 August 2020

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 243 KB)

    Published:
    15 June 2020
  • Committee papers (PDF 5.43 MB)

    Published:
    15 June 2020
  • Public committee slides (PDF 545 KB)

    Published:
    15 June 2020

Invitation to participate

  • Final scope (PDF 213 KB)

    Published:
    21 March 2019
  • Draft scope and provisional stakeholder list comments table (post-referral) (PDF 259 KB)

    Published:
    21 March 2019
  • Equality impact assessment (Scoping) (PDF 122 KB)

    Published:
    21 March 2019
  • Final stakeholder list (PDF 209 KB)

    Published:
    21 March 2019

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 373 KB)

    Published:
    06 February 2019
  • Draft matrix post referral (PDF 341 KB)

    Published:
    06 February 2019
Back to top